It is likely that patients with MASLD have resistance to the actions of glucagon, resulting in increased circulating amino acids, which stimulate the pancreas to secrete further glucagon (Suppli et al. 2016, Wewer Albrechtsen et al. 2018). Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.